Literature DB >> 20386556

Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.

Stavroula Kyriazi1, Stan B Kaye, Nandita M deSouza.   

Abstract

Peritoneal metastases are often the first presentation of ovarian malignancy. Evaluating the extent of disease critically determines tumor resectability and can also predict outcome. Standard CT, however, frequently fails to identify small sites of peritoneal spread. Moreover, it does not provide a quantitative index of disease response to cytotoxic therapy as it relies on macroscopic morphological changes in tumor volume, and does not reflect preceding molecular events in the microenvironment of the tumor. We describe the emerging role of functional imaging techniques, such as radioimmunoscintigraphy, PET/CT, diffusion-weighted MRI, dynamic contrast-enhanced MRI, and magnetic resonance spectroscopy in staging ovarian cancer and assessing treatment response. The combination of functional information with conventional anatomical visualization holds promise to accurately characterize peritoneal disease, and provides noninvasive biomarkers of therapeutic performance and patient prognosis.

Entities:  

Mesh:

Year:  2010        PMID: 20386556     DOI: 10.1038/nrclinonc.2010.47

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  141 in total

Review 1.  The effects of microscopic tissue parameters on the diffusion weighted magnetic resonance imaging experiment.

Authors:  D G Norris
Journal:  NMR Biomed       Date:  2001-04       Impact factor: 4.044

2.  Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

Authors:  Norbert Avril; Stefanie Sassen; Barbara Schmalfeldt; Joerg Naehrig; Stephan Rutke; Wolfgang A Weber; Martin Werner; Henner Graeff; Markus Schwaiger; Walther Kuhn
Journal:  J Clin Oncol       Date:  2005-09-12       Impact factor: 44.544

3.  Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen.

Authors:  Adam C Braithwaite; Brian M Dale; Daniel T Boll; Elmar M Merkle
Journal:  Radiology       Date:  2008-12-18       Impact factor: 11.105

Review 4.  Whole-body diffusion-weighted magnetic resonance imaging.

Authors:  Thomas C Kwee; Taro Takahara; Reiji Ochiai; Kazuhiro Katahira; Marc Van Cauteren; Yutaka Imai; Rutger A J Nievelstein; Peter R Luijten
Journal:  Eur J Radiol       Date:  2009-04-28       Impact factor: 3.528

5.  1H-magnetic resonance spectroscopy: a new technique to discriminate benign from malignant ovarian tumors.

Authors:  L F Massuger; P B van Vierzen; U Engelke; A Heerschap; R Wevers
Journal:  Cancer       Date:  1998-05-01       Impact factor: 6.860

6.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

Authors:  G J Rustin; A E Nelstrop; P McClean; M F Brady; W P McGuire; W J Hoskins; H Mitchell; H E Lambert
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

7.  Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI.

Authors:  Russell N Low; Jonathan Gurney
Journal:  J Magn Reson Imaging       Date:  2007-04       Impact factor: 4.813

8.  Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck.

Authors:  Sungheon Kim; Laurie Loevner; Harry Quon; Eric Sherman; Gregory Weinstein; Alex Kilger; Harish Poptani
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

9.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

10.  Evaluation of computed tomography in patients with peritoneal carcinomatosis.

Authors:  P Jacquet; J S Jelinek; M A Steves; P H Sugarbaker
Journal:  Cancer       Date:  1993-09-01       Impact factor: 6.860

View more
  39 in total

1.  Preclinical evaluation of Mab CC188 for ovarian cancer imaging.

Authors:  M Xu; M P Rettig; G Sudlow; B Wang; W J Akers; D Cao; D G Mutch; J F DiPersio; S Achilefu
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

2.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

3.  Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo.

Authors:  Prabodh K Kandala; Sanjay K Srivastava
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

4.  The clinical value of dynamic contrast-enhanced MRI in differential diagnosis of malignant and benign ovarian lesions.

Authors:  Xian Li; Jun-Li Hu; Lai-Min Zhu; Xin-Hai Sun; Hua-Qiang Sheng; Ning Zhai; Xi-Bin Hu; Chu-Ran Sun; Bin Zhao
Journal:  Tumour Biol       Date:  2015-02-28

5.  Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.

Authors:  Dawei Jiang; Hyung-Jun Im; Haiyan Sun; Hector F Valdovinos; Christopher G England; Emily B Ehlerding; Robert J Nickles; Dong Soo Lee; Steve Y Cho; Peng Huang; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-06       Impact factor: 9.236

6.  Outcome of Bowel Resection in Women with Advanced Ovarian Carcinoma.

Authors:  Ajit Sebastian; Anitha Thomas; Gigi Varghese; Bijesh Yadav; Rachel Chandy; Abraham Peedicayil
Journal:  Indian J Surg Oncol       Date:  2018-07-20

7.  Radiomics based on multisequence magnetic resonance imaging for the preoperative prediction of peritoneal metastasis in ovarian cancer.

Authors:  Xiao-Li Song; Jia-Liang Ren; Ting-Yu Yao; Dan Zhao; Jinliang Niu
Journal:  Eur Radiol       Date:  2021-05-04       Impact factor: 5.315

8.  In vivo pentamodal tomographic imaging for small animals.

Authors:  Muhan Liu; Hongbo Guo; Hongbo Liu; Zeyu Zhang; Chongwei Chi; Hui Hui; Di Dong; Zhenhua Hu; Jie Tian
Journal:  Biomed Opt Express       Date:  2017-02-06       Impact factor: 3.732

9.  Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.

Authors:  Thomas E Liggett; Anatoliy Melnikov; Qilong Yi; Charles Replogle; Wei Hu; Jacob Rotmensch; Aparna Kamat; Anil K Sood; Victor Levenson
Journal:  Gynecol Oncol       Date:  2010-11-06       Impact factor: 5.482

10.  Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.

Authors:  Katrijn Michielsen; Ignace Vergote; Katya Op de Beeck; Frederic Amant; Karin Leunen; Philippe Moerman; Christophe Deroose; Geert Souverijns; Steven Dymarkowski; Frederik De Keyzer; Vincent Vandecaveye
Journal:  Eur Radiol       Date:  2013-12-11       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.